238 related articles for article (PubMed ID: 14599607)
1. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.
Cheng TY; Grubbs E; Abdul-Wahab O; Leu SY; Hung CF; Petros W; Aloia T; Fedrau R; Pruitt S; Colvin M; Friedman H; Tyler D
Am J Surg; 2003 Nov; 186(5):460-7. PubMed ID: 14599607
[TBL] [Abstract][Full Text] [Related]
2. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
3. Continuous leakage measurement during hyperthermic isolated limb perfusion.
Daryanani D; Komdeur R; Ter Veen J; Nijhuis PH; Piers DA; Hoekstra HJ
Ann Surg Oncol; 2001 Aug; 8(7):566-72. PubMed ID: 11508617
[TBL] [Abstract][Full Text] [Related]
4. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
5. A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity.
Byrne DS; McKay AJ; Blackie R; MacKie RM
Eur J Cancer; 1996 Nov; 32A(12):2082-7. PubMed ID: 9014749
[TBL] [Abstract][Full Text] [Related]
6. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
[TBL] [Abstract][Full Text] [Related]
7. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
Lejeune FJ; Eggermont AM
J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
[No Abstract] [Full Text] [Related]
9. [Regional chemotherapy--perfusion of the extremities].
Meyer T; Göhl J
Kongressbd Dtsch Ges Chir Kongr; 2001; 118():200-4. PubMed ID: 11824246
[TBL] [Abstract][Full Text] [Related]
10. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
Thompson JF; Gianoutsos MP
World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
[TBL] [Abstract][Full Text] [Related]
11. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb.
Huber R; Krüger I; Kuper K; Huber PM; Pichlmaier H
Am J Surg; 1995 Oct; 170(4):345-52. PubMed ID: 7573726
[TBL] [Abstract][Full Text] [Related]
12. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
13. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
Olieman AF; Liénard D; Eggermont AM; Kroon BB; Lejeune FJ; Hoekstra HJ; Koops HS
Arch Surg; 1999 Mar; 134(3):303-7. PubMed ID: 10088573
[TBL] [Abstract][Full Text] [Related]
16. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial.
Olofsson Bagge R; Mattsson J; Hafström L
Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ
Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165
[TBL] [Abstract][Full Text] [Related]
18. [Anti-blastic hyperthermic perfusion in the treatment of melanoma of the extremities in the loco-regional diffusion phase].
Di Filippo F; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S
Tumori; 2003; 89(4 Suppl):241-3. PubMed ID: 12903606
[TBL] [Abstract][Full Text] [Related]
19. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
20. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
Pace M; Gattai R; Mascitelli EM; Millanta L
J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]